/IXSBF

IXSBF Stock - InNexus Biotechnology, Inc.

Q: What is the analyst price target for IXSBF?

Analyst price target information is not currently available for IXSBF.

Q: What is IXSBF's market cap?

Market capitalization information is not currently available for IXSBF.

Healthcare|Medical - Pharmaceuticals|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Nov 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IXSBF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2005

FY2006

FY2007

FY2008

FY2009

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-29.05

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2009	FY2008	FY2007	FY2006	FY2005
Revenue	N/A	N/A	$1,010	$15,274	$46,359
Gross Profit	N/A	N/A	$-610,074	$-241,913	$-161,281
Gross Margin	N/A	N/A	-60403.4%	-1583.8%	-347.9%
Operating Income	$-3,929,961	$-6,702,325	$-5,712,230	$-5,132,608	$-2,669,431
Net Income	$-6,688,684	$-8,017,224	$-5,887,642	$-5,172,010	$-2,932,875
Net Margin	N/A	N/A	-582934.9%	-33861.5%	-6326.4%
EPS	$-0.07	$-0.11	$-0.11	$-0.13	$-0.12

Company Overview

InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.

Frequently Asked Questions about IXSBF

What is IXSBF's current stock price?

InNexus Biotechnology, Inc. (IXSBF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for IXSBF?

No analyst price targets are currently available for this stock.

What sector is InNexus Biotechnology, Inc. in?

InNexus Biotechnology, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the OTC exchange.

What is IXSBF's market cap?

InNexus Biotechnology, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does IXSBF pay dividends?

No, InNexus Biotechnology, Inc. does not currently pay a dividend to shareholders.